Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26981434 | 1.00 | LTA4H (0.35) | LTA4HGRIN1GRIN2BCARM1PRMT6 | |
| SCHEMBL6043388 | 0.89 | LTA4H (0.33) | LTA4HGRIN1GRIN2B | |
| SCHEMBL26981363 | 0.83 | — | — | |
| SCHEMBL771319 | 0.83 | — | — | |
| SCHEMBL10152381 | 0.82 | DRD2 (0.41) | HRH3DRD2 | |
| SCHEMBL15685442 | 0.82 | DRD2 (0.41) | HRH3DRD2 | |
| SCHEMBL15133969 | 0.82 | DRD2 (0.41) | HRH3DRD2 | |
| SCHEMBL25363068 | 0.80 | ALOX15 (0.41) | LTA4HGRIN1GRIN2BCARM1PRMT6 | |
| SCHEMBL15685469 | 0.80 | SLC18A3 (0.37) | LTA4HGRIN1GRIN2B | |
| SCHEMBL6043375 | 0.80 | GRIN1 (0.37) | LTA4HGRIN1GRIN2BKCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| CN-117255684-A | Quinazolinamine derivatives as KRAS inhibitors | 尼坎治疗公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-2805956-B1 | GAMBOGENIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NINTH PEOPLES HOSPITAL SCHOOL MEDICINE SHANGHAI JIAO TONG UNIV (CN) | 2018-12-26 | — | — | EP | disclosed |
| EP-2805956-A1 | GAMBOGENIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | Ninth People's Hospital, School Medicine Shanghai Jiao Tong University (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | LTA4H 900/4885GRIN1 673/4885GRIN2B 699/4885 |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | LTA4H 4413/4885GRIN1 2592/4885GRIN2B 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.